The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period
Abstract
In the normal course of the delivery of care, anesthesiologists encounter many patients who are receiving drugs that affect platelet function as a fundamental part of primary and secondary management of atherosclerotic thrombotic disease. There are several antiplatelet drugs available for use in clinical practice and several under investigation. Aspirin and clopidogrel (alone and in combination) have been the most studied and have the most favorable risk-benefit profiles of drugs currently available. Prasugrel was recently approved for patients with acute coronary syndrome undergoing percutaneous interventions. Other drugs such as dipyridamole and cilostazol have not been as extensively investigated. There are several newer investigational drugs such as cangrelor and ticagrelor, but whether they confer significant additional benefits remains to be established. Management of patients who are receiving antiplatelet drugs during the perioperative period requires an understanding of the underlying pathology and rationale for their administration, pharmacology and pharmacokinetics, and drug interactions. Furthermore, the risk and benefit assessment of discontinuing or continuing these drugs should be made bearing in mind the proposed surgery and its inherent risk for bleeding complications as well as decisions relating to appropriate use of general or some form of regional anesthesia. In general, the safest approach to prevent thrombosis seems to be continuation of these drugs throughout the perioperative period except where concerns about perioperative bleeding outweigh those associated with the development of thrombotic occlusion. Knowledge of the pharmacodynamics and pharmacokinetics of antiplatelet drugs may allow practitioners to anticipate difficulties associated with drug withdrawal and administration in the perioperative period including the potential for drug interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790 · cited 2×
“32).(172) There was a higher incidence of life-threatening bleeding (1.”
BackgroundMethod(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R. C., Olin, J. W., Puschett, J. B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174526 · Cited by 3,708
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
Gurbel, P. A., Bliden, K. P., Butler, K., Tantry, U. S., Gesheff, T., Wei, C., Teng, R., Antonino, M. J., Patil, S. B., Karunakaran, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.912550 · Cited by 1,159
THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., & Zeldin, D. C. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008672 · Cited by 870
Wiviott, S. D., Braunwald, E., Angiolillo, D. J., Meisel, S., Dalby, A. J., Verheugt, F. W. A., Goodman, S. G., Corbalan, R., Purdy, D. A., Murphy, S. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.791061 · Cited by 754
Aspirin and Mortality from Coronary Bypass Surgery
Mangano, D. T. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020798 · Cited by 674
Research works printed but not linked: 283
- Jennings, 2009, Role of platelets in atherothrombosis., Am J Cardiol, 103, 4A, 10.1016/j.amjcard.2008.11.017 · DOI · Paper page
- Bhatt, 2009, Role of antiplatelet therapy across the spectrum of patients with coronary artery disease., Am J Cardiol, 103, 11A, 10.1016/j.amjcard.2008.11.018 · DOI
- Hirsh, 2008, Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 71S, 10.1378/chest.08-0693 · DOI · Paper page
- Albers, 2008, Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 630S, 10.1378/chest.08-0720 · DOI · Paper page
- Hankey, 2000, Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients., Cochrane Database Syst Rev, 2, CD001246
- Leonardi-Bee, 2005, Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials., Stroke, 36, 162, 10.1161/01.STR.0000149621.95215.ea · DOI
- 2002, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients., BMJ, 324, 71, 10.1136/bmj.324.7329.71 · DOI · Paper page
- Goodman, 2008, Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 708S, 10.1378/chest.08-0665 · DOI
- Harrington, 2008, Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 670S, 10.1378/chest.08-0691 · DOI
- Grines, 2007, Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians., Catheter Cardiovasc Interv, 69, 334, 10.1002/ccd.21124 · doi:10.1002/ccd.21124
- Helton, 2007, Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials., Am J Cardiovasc Drugs, 7, 289, 10.2165/00129784-200707040-00006 · DOI
- Sun, 2008, The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies., Eur Heart J, 29, 1057, 10.1093/eurheartj/ehn104 · DOI
- Purkayastha, 2006, Does clopidogrel affect outcome after coronary artery bypass grafting A meta-analysis., Heart, 92, 531, 10.1136/hrt.2004.058396 · DOI
- Zimmermann, 2008, Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent., Eur J Cardiothorac Surg, 34, 93, 10.1016/j.ejcts.2008.03.023 · DOI
- Eidelman, 2003, An update on aspirin in the primary prevention of cardiovascular disease., Arch Intern Med, 163, 2006, 10.1001/archinte.163.17.2006 · DOI · Paper page
- Hayden, 2002, Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force., Ann Intern Med, 136, 161, 10.7326/0003-4819-136-2-200201150-00016 · DOI · Paper page
- Becker, 2008, The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 776S, 10.1378/chest.08-0685 · DOI · Paper page
- Robless, 2001, Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease., Br J Surg, 88, 787, 10.1046/j.0007-1323.2001.01774.x · DOI · Paper page
- Weisman, 2002, Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events., Arch Intern Med, 162, 2197, 10.1001/archinte.162.19.2197 · DOI · Paper page
- Burger, 2005, Low-dose aspirin for secondary cardiovascular prevention: cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuationreview and meta-analysis., J Intern Med, 257, 399, 10.1111/j.1365-2796.2005.01477.x · DOI · Paper page
- Berger, 2009, Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials., JAMA, 301, 1909, 10.1001/jama.2009.623 · DOI · Paper page
- Hiatt, 2002, Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy., J Intern Med, 251, 193, 10.1046/j.1365-2796.2002.00947.x · DOI
- Girolami, 2000, Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis., Eur J Vasc Endovasc Surg, 19, 370, 10.1053/ejvs.1999.1034 · DOI
- Sobel, 2008, Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 815S, 10.1378/chest.08-0686 · DOI · Paper page
- Singer, 2008, Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 546S, 10.1378/chest.08-0678 · DOI · Paper page
- Gladding, 2008, Antiplatelet drug nonresponsiveness., Am Heart J, 155, 591, 10.1016/j.ahj.2007.12.034 · DOI
- Newsome, 2008, Coronary artery stents. II. Perioperative considerations and management., Anesth Analg, 107, 570, 10.1213/ane.0b013e3181731e95 · DOI
- Patrono, 2008, Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 199S, 10.1378/chest.08-0672 · DOI · Paper page
- Benedek, 1995, Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers., J Clin Pharmacol, 35, 1181, 10.1002/j.1552-4604.1995.tb04044.x · DOI
- Buerke, 1995, Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses., Am Heart J, 130, 465, 10.1016/0002-8703(95)90353-4 · DOI
- Bochner, 1988, Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function., Eur J Clin Pharmacol, 35, 287, 10.1007/BF00558267 · DOI
- Roth, 1975, Acetylation of prostaglandin synthase by aspirin., Proc Natl Acad Sci USA, 72, 3073, 10.1073/pnas.72.8.3073 · DOI · Paper page
- Burch, 1978, Inhibition of platelet prostaglandin synthetase by oral aspirin., J Clin Invest, 61, 314, 10.1172/JCI108941 · DOI · Paper page
- Vane, 1995, New insights into the mode of action of anti-inflammatory drugs., Inflamm Res, 44, 1, 10.1007/BF01630479 · DOI · Paper page
- Patrignani, 1982, Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects., J Clin Invest, 69, 1366, 10.1172/JCI110576 · DOI · Paper page
- Pierucci, 1989, Improvement of renal function with selective thromboxane antagonism in lupus nephritis., N Engl J Med, 320, 421, 10.1056/NEJM198902163200703 · doi:10.1056/nejm198902163200703
- Serebruany, 2004, Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials., Am J Hematol, 75, 40, 10.1002/ajh.10451 · DOI · Paper page
- Derry, 2000, Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis., BMJ, 321, 1183, 10.1136/bmj.321.7270.1183 · DOI · Paper page
- Lai, 2002, Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use., N Engl J Med, 346, 2033, 10.1056/NEJMoa012877 · DOI · Paper page
- Capone, 2005, Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects., J Am Coll Cardiol, 45, 1295, 10.1016/j.jacc.2005.01.045 · DOI · Paper page
- MacDonald, 2003, Effect of ibuprofen on cardioprotective effect of aspirin., Lancet, 361, 573, 10.1016/S0140-6736(03)12509-3 · DOI · Paper page
- Kurth, 2003, Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs., Circulation, 108, 1191, 10.1161/01.CIR.0000087593.07533.9B · DOI · Paper page
- Gladding, 2008, The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers., Am J Cardiol, 101, 1060, 10.1016/j.amjcard.2007.11.054 · DOI · Paper page
- Kimmel, 2002, Parenteral ketorolac and risk of myocardial infarction., Pharmacoepidemiol Drug Saf, 11, 113, 10.1002/pds.670 · DOI
- Kearney, 2006, Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis Meta-analysis of randomised trials., BMJ, 332, 1302, 10.1136/bmj.332.7553.1302 · DOI · Paper page
- Antman, 2007, Use of nonsteroidal antiinflammatory drugs: an update for cliniciansa scientific statement from the American Heart Association., Circulation, 115, 1634, 10.1161/CIRCULATIONAHA.106.181424 · DOI · Paper page
- Graham, 2005, Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study., Lancet, 365, 475, 10.1016/S0140-6736(05)17864-7 · DOI · Paper page
- Nussmeier, 2005, Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery., N Engl J Med, 352, 1081, 10.1056/NEJMoa050330 · DOI · Paper page
- Angiolillo, 2009, Variability in responsiveness to oral antiplatelet therapy., Am J Cardiol, 103, 27A, 10.1016/j.amjcard.2008.11.020 · DOI
- Cattaneo, 2007, Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection., J Thromb Haemost, 5, 230, 10.1111/j.1538-7836.2007.02498.x · DOI · Paper page
- Hovens, 2007, Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review., Am Heart J, 153, 175, 10.1016/j.ahj.2006.10.040 · DOI · Paper page
- Krasopoulos, 2008, Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis., BMJ, 336, 195, 10.1136/bmj.39430.529549.BE · DOI · Paper page
- Schwartz, 2005, Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction., Am J Cardiol, 95, 973, 10.1016/j.amjcard.2004.12.038 · DOI · Paper page
- Serebruany, 2006, Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial., Int J Clin Pract, 60, 863, 10.1111/j.1742-1241.2006.00999.x · DOI
- Eikelboom, 2008, Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk., Circulation, 118, 1705, 10.1161/CIRCULATIONAHA.108.768283 · DOI · Paper page
- Bonello, 2008, Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study., J Am Coll Cardiol, 51, 1404, 10.1016/j.jacc.2007.12.044 · DOI · Paper page
- Cipollone, 2000, Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina., Circulation, 102, 1007, 10.1161/01.CIR.102.9.1007 · DOI · Paper page
- Marcucci, 2006, Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events., Am J Cardiol, 98, 1156, 10.1016/j.amjcard.2006.05.041 · doi:10.1016/j.amjcard.2006.05.041
- DiChiara, 2007, The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study., Diabetes, 56, 3014, 10.2337/db07-0707 · DOI · Paper page
- Hall, 1997, Light versus heavy sedation after cardiac surgery: myocardial ischemia and the stress response. Maritime Heart Centre and Dalhousie University., Anesth Analg, 85, 971, 10.1213/00000539-199711000-00004 · doi:10.1213/00000539-199711000-00004
- Fabre, 2010, Limitations of current therapies to prevent thrombosis: a need for novel strategies., Mol Biosyst, 6, 305, 10.1039/B914375K · DOI
- Gurbel, 2009, The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting., Platelets, 20, 97, 10.1080/09537100802687666 · DOI
- van der Poll, 1990, Activation of coagulation after administration of tumor necrosis factor to normal subjects., N Engl J Med, 322, 1622, 10.1056/NEJM199006073222302 · DOI · Paper page
- Aird, 2001, Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis., Crit Care Med, 29, S28, 10.1097/00003246-200107001-00013 · DOI · Paper page
- Steinhubl, 2007, Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease., Vasc Med, 12, 113, 10.1177/1358863X07077462 · DOI
- Rough, 2009, Beta2 adrenoreceptor blockade attenuates the hyperinflammatory response induced by traumatic injury., Surgery, 145, 235, 10.1016/j.surg.2008.09.013 · DOI
- Flierl, 2009, Upregulation of phagocyte-derived catecholamines augments the acute inflammatory response., PLoS One, 4, e4414, 10.1371/journal.pone.0004414 · DOI · Paper page
- Anfossi, 1996, Role of catecholamines in platelet function: pathophysiological and clinical significance., Eur J Clin Invest, 26, 353, 10.1046/j.1365-2362.1996.150293.x · DOI · Paper page
- Beres, 2008, Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy., Thromb Haemost, 100, 829, 10.1160/TH08-03-0158 · DOI
- Larsson, 1994, Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin., Circulation, 89, 1951, 10.1161/01.CIR.89.5.1951 · DOI · Paper page
- Golanski, 2001, Platelet hyperreactivity after coronary artery bypass grafting: the possible relevance to glycoprotein polymorphismsa preliminary report., Platelets, 12, 241
- Feher, 2009, The genetics of antiplatelet drug resistance., Clin Genet, 75, 1, 10.1111/j.1399-0004.2008.01105.x · DOI
- Hu, 2006, Chronic beta-adrenergic receptor stimulation induces cardiac apoptosis and aggravates myocardial ischemiareperfusion injury by provoking inducible nitric-oxide synthase-mediated nitrative stress., J Pharmacol Exp Ther, 318, 469, 10.1124/jpet.106.102160 · DOI
- Golanski, 2005, Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on the monitoring of aspirin antiplatelet therapy., Ther Drug Monit, 27, 484, 10.1097/01.ftd.0000158084.84071.41 · DOI
- Mardikar, 2008, Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in a high risk population., J Assoc Physicians India, 56, 321
- Lordkipanidze, 2006, Aspirin resistance: truth or dare., Pharmacol Ther, 112, 733, 10.1016/j.pharmthera.2006.05.011 · DOI
- Hankey, 2006, Aspirin resistance., Lancet, 367, 606, 10.1016/S0140-6736(06)68040-9 · DOI · Paper page
- Abaci, 2005, Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes., Thromb Res, 116, 465, 10.1016/j.thromres.2005.02.005 · DOI
- Cornelissen, 2006, Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function., Thromb Haemost, 95, 476, 10.1160/TH05-10-0649 · doi:10.1160/th05-10-0649
- Lim, 2003, Indirect comparison meta-analysis of aspirin therapy after coronary surgery., BMJ, 327, 1309, 10.1136/bmj.327.7427.1309 · DOI
- Duzenli, 2008, Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin., Am J Cardiol, 102, 396, 10.1016/j.amjcard.2008.03.074 · DOI · Paper page
- Lev, 2006, Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance., J Am Coll Cardiol, 47, 27, 10.1016/j.jacc.2005.08.058 · DOI · Paper page
- Sanderson, 2005, Narrative review: aspirin resistance and its clinical implications., Ann Intern Med, 142, 370, 10.7326/0003-4819-142-5-200503010-00012 · DOI · Paper page
- Pamukcu, 2007, A review of aspirin resistance: definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes., J Thromb Thrombolysis, 23, 213, 10.1007/s11239-006-9043-2 · DOI
- Macchi, 2006, Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance., Curr Pharm Des, 12, 251, 10.2174/138161206775193064 · DOI
- Michelson, 2005, Aspirin resistance: position paper of the Working Group on Aspirin Resistance., J Thromb Haemost, 3, 1309, 10.1111/j.1538-7836.2005.01351.x · DOI · Paper page
- Frelinger, 2006, Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance., Circulation, 113, 2888, 10.1161/CIRCULATIONAHA.105.596627 · DOI · Paper page
- Wang, 2006, Aspirin and clopidogrel resistance: an emerging clinical entity., Eur Heart J, 27, 647, 10.1093/eurheartj/ehi684 · DOI · Paper page
- Serebruany, 2008, Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients., Fundam Clin Pharmacol, 22, 315, 10.1111/j.1472-8206.2008.00582.x · doi:10.1111/j.1472-8206.2008.00582.x
- Adams, 2008, Update to the AHAASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack., Stroke, 39, 1647, 10.1161/STROKEAHA.107.189063 · DOI · Paper page
- Taubert, 2004, Pharmacokinetics of clopidogrel after administration of a high loading dose., Thromb Haemost, 92, 311, 10.1160/TH04-02-0105 · DOI · Paper page
- Lins, 1999, Pharmacokinetic profile of 14C-labeled clopidogrel., Semin Thromb Hemost, 25, 29
- Hulot, 2006, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects., Blood, 108, 2244, 10.1182/blood-2006-04-013052 · DOI · Paper page
- Farid, 2007, Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently., Clin Pharmacol Ther, 81, 735, 10.1038/sj.clpt.6100139 · DOI · Paper page
- Serebruany, 2005, Variability in platelet responsiveness to clopidogrel among 544 individuals., J Am Coll Cardiol, 45, 246, 10.1016/j.jacc.2004.09.067 · DOI · Paper page
- Shuldiner, 2009, Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy., JAMA, 302, 849, 10.1001/jama.2009.1232 · DOI · Paper page
- Mega, 2009, Cytochrome p-450 polymorphisms and response to clopidogrel., N Engl J Med, 360, 354, 10.1056/NEJMoa0809171 · DOI · Paper page
- Bonello-Palot, 2009, Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention., Am J Cardiol, 104, 1511, 10.1016/j.amjcard.2009.07.015 · doi:10.1016/j.amjcard.2009.07.015
- von Beckerath, 2005, Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial., Circulation, 112, 2946, 10.1161/CIRCULATIONAHA.105.559088 · DOI · Paper page
- Deray, 1998, Clopidogrel activities in patients with renal impairment., Clin Drug Invest, 16, 319, 10.2165/00044011-199816040-00006 · DOI
- Slugg, 2000, Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel., J Clin Pharmacol, 40, 396, 10.1177/00912700022008973 · doi:10.1177/00912700022008973
- Hochholzer, 2005, Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention., Circulation, 111, 2560, 10.1161/01.CIR.0000160869.75810.98 · DOI
- Taubert, 2006, Impact of P-glycoprotein on clopidogrel absorption., Clin Pharmacol Ther, 80, 486, 10.1016/j.clpt.2006.07.007 · DOI
- Ding, 2003, Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270., Blood, 101, 3908, 10.1182/blood-2002-10-3027 · DOI · Paper page
- Suh, 2006, Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel., CMAJ, 174, 1715, 10.1503/cmaj.060664 · DOI · Paper page
- Ho, 2008, Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome., JAMA, 299, 532, 10.1001/jama.299.5.532 · DOI · Paper page
- Sibbing, 2010, A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment., J Am Coll Cardiol, 55, 558, 10.1016/j.jacc.2009.09.038 · doi:10.1016/j.jacc.2009.09.038
- Berger, 2008, Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis., J Am Coll Cardiol, 52, 1693, 10.1016/j.jacc.2008.08.031 · DOI · Paper page
- Chen, 2004, Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting., J Thorac Cardiovasc Surg, 128, 425, 10.1016/j.jtcvs.2004.02.019 · DOI · Paper page
- Chan, 2007, Clopidogrel is safe early after on- and off-pump coronary artery bypass surgery., J Card Surg, 22, 493, 10.1111/j.1540-8191.2007.00475.x · doi:10.1111/j.1540-8191.2007.00475.x
- Harker, 1999, Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events., Drug Saf, 21, 325, 10.2165/00002018-199921040-00007 · DOI
- Bennett, 2000, Thrombotic thrombocytopenic purpura associated with clopidogrel., N Engl J Med, 342, 1773, 10.1056/NEJM200006153422402 · DOI · Paper page
- Lau, 2003, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction., Circulation, 107, 32, 10.1161/01.CIR.0000047060.60595.CC · DOI · Paper page
- Saw, 2007, Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial., J Am Coll Cardiol, 50, 291, 10.1016/j.jacc.2007.01.097 · DOI · Paper page
- Lotfi, 2008, High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients: a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis., Am Heart J, 155, 954, 10.1016/j.ahj.2007.12.009 · DOI
- Trenk, 2008, Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement., Thromb Haemost, 99, 174, 10.1160/TH07-08-0503 · doi:10.1160/th07-08-0503
- Brophy, 2006, A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention., Am Heart J, 152, 263, 10.1016/j.ahj.2005.08.023 · DOI
- Neubauer, 2006, Thienopyridines and statins: assessing a potential drug-drug interaction., Curr Pharm Des, 12, 1271, 10.2174/138161206776361354 · doi:10.2174/138161206776361354
- Gilard, 2008, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study., J Am Coll Cardiol, 51, 256, 10.1016/j.jacc.2007.06.064 · DOI · Paper page
- Small, 2008, Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel., J Clin Pharmacol, 48, 475, 10.1177/0091270008315310 · DOI · Paper page
- Ho, 2009, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome., JAMA, 301, 937, 10.1001/jama.2009.261 · DOI · Paper page
- Rassen, 2009, Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome., Circulation, 120, 2322, 10.1161/CIRCULATIONAHA.109.873497 · DOI · Paper page
- Juurlink, 2009, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel., CMAJ, 180, 713, 10.1503/cmaj.082001 · DOI · Paper page
- Bhatt, 2008, ACCFACGAHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents., Circulation, 118, 1894, 10.1161/CIRCULATIONAHA.108.191087 · DOI · Paper page
- Hirota, 2005, The efficacy of preanesthetic proton pump inhibitor treatment for patients on long-term H2 antagonist therapy., Anesth Analg, 101, 1038, 10.1213/01.ane.0000166979.99225.a0 · doi:10.1213/01.ane.0000166979.99225.a0
- Devlin, 2005, Proton pump inhibitor formulary considerations in the acutely ill. Part 2. Clinical efficacy, safety, and economics., Ann Pharmacother, 39, 1844, 10.1345/aph.1G176 · DOI
- Ivandic, 2006, Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor., Clin Chem, 52, 383, 10.1373/clinchem.2005.059535 · doi:10.1373/clinchem.2005.059535
- Snoep, 2007, Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis., Am Heart J, 154, 221, 10.1016/j.ahj.2007.04.014 · DOI · Paper page
- Matetzky, 2004, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction., Circulation, 109, 3171, 10.1161/01.CIR.0000130846.46168.03 · DOI · Paper page
- Serebruany, 2007, The clopidogrel resistance trap., Am J Cardiol, 100, 1044, 10.1016/j.amjcard.2007.04.050 · DOI
- Jackevicius, 2008, Cardiovascular outcomes after a change in prescription policy for clopidogrel., N Engl J Med, 359, 1802, 10.1056/NEJMsa0803410 · DOI
- Spertus, 2006, Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry., Circulation, 113, 2803, 10.1161/CIRCULATIONAHA.106.618066 · DOI · Paper page
- Gurbel, 2003, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity., Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83 · DOI · Paper page
- Michelson, 2006, Resistance to antiplatelet drugs., Eur Heart J, 8, G53, 10.1093/eurheartj/sul056 · doi:10.1093/eurheartj/sul056
- Tassies, 2006, Pharmacogenetics of antithrombotic drugs., Curr Pharm Des, 12, 2425, 10.2174/138161206777698963 · doi:10.2174/138161206777698963
- Siller-Matula, 2007, Thienopyridines in cardiovascular disease: focus on clopidogrel resistance., Thromb Haemost, 97, 385, 10.1160/TH06-08-0420 · doi:10.1160/th06-08-0420
- Gori, 2008, Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents., J Am Coll Cardiol, 52, 734, 10.1016/j.jacc.2008.05.032 · doi:10.1016/j.jacc.2008.05.032
- Gurbel, 2005, The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting., J Am Coll Cardiol, 45, 1392, 10.1016/j.jacc.2005.01.030 · DOI · Paper page
- Fontana, 2008, Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C192 allele on clopidogrel responsiveness., Thromb Res, 121, 463, 10.1016/j.thromres.2007.06.012 · doi:10.1016/j.thromres.2007.06.012
- Abuzahra, 2008, Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents., Am J Cardiol, 102, 401, 10.1016/j.amjcard.2008.03.073 · doi:10.1016/j.amjcard.2008.03.073
- Perneby, 2007, Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease., Thromb Haemost, 98, 1316, 10.1160/TH07-05-0323 · doi:10.1160/th07-05-0323
- Lim, 2004, Clopidogrel did not inhibit platelet function early after coronary bypass surgery: a prospective randomized trial., J Thorac Cardiovasc Surg, 128, 432, 10.1016/j.jtcvs.2004.03.007 · DOI
- Erlinge, 2008, Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo., J Am Coll Cardiol, 52, 1968, 10.1016/j.jacc.2008.07.068 · DOI · Paper page
- Marcucci, 2007, Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy., Thromb Haemost, 98, 844, 10.1160/TH06-11-0618 · DOI
- David, 1999, Antiplatelet activity of clopidogrel in coronary artery bypass graft surgery patients., Thromb Haemost, 82, 1417, 10.1055/s-0037-1614847 · DOI
- Angiolillo, 2009, Advances in antiplatelet therapy: agents in clinical development., Am J Cardiol, 103, 40A, 10.1016/j.amjcard.2008.11.023 · DOI
- Niitsu, 2005, Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity., Semin Thromb Hemost, 31, 184, 10.1055/s-2005-869524 · DOI · Paper page
- Jakubowski, 2007, Prasugrel: a novel thienopyridine antiplatelet agenta review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile., Cardiovasc Drug Rev, 25, 357, 10.1111/j.1527-3466.2007.00027.x · DOI · Paper page
- Wiviott, 2005, Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial., Circulation, 111, 3366, 10.1161/CIRCULATIONAHA.104.502815 · DOI · Paper page
- Wiviott, 2007, Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial., Circulation, 116, 2923, 10.1161/CIRCULATIONAHA.107.740324 · DOI · Paper page
- Wiviott, 2008, Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial., Lancet, 371, 1353, 10.1016/S0140-6736(08)60422-5 · DOI · Paper page
- Montalescot, 2009, Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial., Lancet, 373, 723, 10.1016/S0140-6736(09)60441-4 · DOI · Paper page
- Murphy, 2008, Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial., Eur Heart J, 29, 2473, 10.1093/eurheartj/ehn362 · DOI
- Sugidachi, 2000, The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties., Br J Pharmacol, 129, 1439, 10.1038/sj.bjp.0703237 · DOI · Paper page
- Rehmel, 2006, Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450., Drug Metab Dispos, 34, 600, 10.1124/dmd.105.007989 · DOI · Paper page
- Wallentin, 2008, Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease., Eur Heart J, 29, 21, 10.1093/eurheartj/ehm545 · DOI · Paper page
- Brandt, 2007, Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel., J Thromb Haemost, 5, 2429, 10.1111/j.1538-7836.2007.02775.x · DOI · Paper page
- Farid, 2007, The disposition of prasugrel, a novel thienopyridine, in humans., Drug Metab Dispos, 35, 1096, 10.1124/dmd.106.014522 · doi:10.1124/dmd.106.014522
- Weerakkody, 2007, Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status., Am J Cardiol, 100, 331, 10.1016/j.amjcard.2007.02.103 · doi:10.1016/j.amjcard.2007.02.103
- Jakubowski, 2006, The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects., J Cardiovasc Pharmacol, 47, 377, 10.1097/01.fjc.0000210069.47205.c0 · DOI
- Jakubowski, 2007, A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans., Br J Clin Pharmacol, 63, 421, 10.1111/j.1365-2125.2006.02792.x · DOI
- Braun, 2008, Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease., Thromb Haemost, 100, 626, 10.1160/TH08-05-0313 · DOI
- Jernberg, 2006, Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease., Eur Heart J, 27, 1166, 10.1093/eurheartj/ehi877 · DOI · Paper page
- Weerakkody, 2007, Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis., J Cardiovasc Pharmacol Ther, 12, 205, 10.1177/1074248407304731 · doi:10.1177/1074248407304731
- Payne, 2008, Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects., Platelets, 19, 275, 10.1080/09537100801891640 · doi:10.1080/09537100801891640
- Serebruany, 2006, Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study., Postgrad Med J, 82, 404, 10.1136/pgmj.2006.047696 · doi:10.1136/pgmj.2006.047696
- Bhatt, 2007, Intensifying platelet inhibition: navigating between Scylla and Charybdis., N Engl J Med, 357, 2078, 10.1056/NEJMe0706859 · DOI · Paper page
- Antman, 2008, Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis., J Am Coll Cardiol, 51, 2028, 10.1016/j.jacc.2008.04.002 · DOI · Paper page
- Farid, 2008, Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects., Pharmacotherapy, 28, 1483, 10.1592/phco.28.12.1483 · DOI
- Oestreich, 2010, Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events., Curr Opin Investig Drugs, 11, 340
- Michelson, 2009, New P2Y12 antagonists., Curr Opin Hematol, 16, 371, 10.1097/MOH.0b013e32832ea2f2 · doi:10.1097/moh.0b013e32832ea2f2
- Gurbel, 2010, The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C192 genotype: first experience in patients., J Thromb Haemost, 8, 43, 10.1111/j.1538-7836.2009.03648.x · DOI
- Cattaneo, 2007, Platelet P2 receptors: old and new targets for antithrombotic drugs., Expert Rev Cardiovasc Ther, 5, 45, 10.1586/14779072.5.1.45 · DOI
- Storey, 2001, Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes., Thromb Haemost, 85, 401, 10.1055/s-0037-1615596 · DOI · Paper page
- Jacobsson, 2002, Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction., Clin Ther, 24, 752, 10.1016/S0149-2918(02)85149-9 · DOI
- Greenbaum, 2007, Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial., Am Heart J, 154, 702, 10.1016/j.ahj.2007.06.001 · DOI
- Bhatt, 2009, Intravenous platelet blockade with cangrelor during PCI., N Engl J Med, 361, 2330, 10.1056/NEJMoa0908629 · DOI · Paper page
- Harrington, 2009, Platelet inhibition with cangrelor in patients undergoing PCI., N Engl J Med, 361, 2318, 10.1056/NEJMoa0908628 · DOI · Paper page
- Fugate, 2006, Cangrelor for treatment of coronary thrombosis., Ann Pharmacother, 40, 925, 10.1345/aph.1G120 · doi:10.1345/aph.1g120
- Ingall, 1999, Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy., J Med Chem, 42, 213, 10.1021/jm981072s · DOI · Paper page
- Storey, 2002, Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease., Platelets, 13, 407, 10.1080/0953710021000024402 · DOI
- Greenbaum, 2006, Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial., Am Heart J, 151, 689, 10.1016/j.ahj.2005.11.014 · DOI · Paper page
- Serebruany, 2007, Dyspnoea after antiplatelet agents: the AZD6140 controversy., Int J Clin Pract, 61, 529, 10.1111/j.1742-1241.2007.01294.x · DOI
- Cannon, 2007, Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial., J Am Coll Cardiol, 50, 1844, 10.1016/j.jacc.2007.07.053 · DOI · Paper page
- Cannon, 2010, Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study., Lancet, 375, 283, 10.1016/S0140-6736(09)62191-7 · DOI · Paper page
- Gurbel, 2010, Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study., Circulation, 121, 1188, 10.1161/CIRCULATIONAHA.109.919456 · DOI · Paper page
- Husted, 2006, Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin., Eur Heart J, 27, 1038, 10.1093/eurheartj/ehi754 · DOI · Paper page
- Teng, 2010, Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects., Eur J Clin Pharmacol, 66, 487, 10.1007/s00228-009-0778-5 · DOI · Paper page
- van Giezen, 2009, Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation., J Thromb Haemost, 7, 1556, 10.1111/j.1538-7836.2009.03527.x · DOI · Paper page
- Storey, 2009, Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3., Platelets, 20, 341, 10.1080/09537100903075324 · DOI
- Storey, 2007, Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes., J Am Coll Cardiol, 50, 1852, 10.1016/j.jacc.2007.07.058 · DOI · Paper page
- Husted, 2010, Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel., Clin Cardiol, 33, 206, 10.1002/clc.20732 · DOI
- Storey, 2010, Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSETOFFSET study., J Am Coll Cardiol, 56, 185, 10.1016/j.jacc.2010.01.062 · DOI · Paper page
- Gamboa, 2005, Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole., Stroke, 36, 2170, 10.1161/01.STR.0000179044.37760.9d · DOI
- De Schryver, 2007, Dipyridamole for preventing stroke and other vascular events in patients with vascular disease., Cochrane Database Syst Rev, 3, CD001820
- Lehmann, 1984, Persantine bioavailability problems., Clin Pharm, 3, 14
- FitzGerald, 1987, Dipyridamole., N Engl J Med, 316, 1247, 10.1056/NEJM198705143162005 · DOI · Paper page
- Derendorf, 2005, Dipyridamole bioavailability in subjects with reduced gastric acidity., J Clin Pharmacol, 45, 845, 10.1177/0091270005276738 · DOI
- Diener, 1996, European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke., J Neurol Sci, 143, 1, 10.1016/S0022-510X(96)00308-5 · DOI · Paper page
- Mahony, 1982, Dipyridamol kinetics., Clin Pharmacol Ther, 31, 330, 10.1038/clpt.1982.42 · doi:10.1038/clpt.1982.42
200 of 283 shown
Cited by
Rossaint, R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Filipescu, D., Hunt, B. J., Komadina, R., Nardi, G., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1265-x · Cited by 1,484
Management of bleeding and coagulopathy following major trauma: an updated European guideline
Spahn, D. R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Filipescu, D., Hunt, B. J., Komadina, R., Nardi, G., et al. (2013) · Critical Care · doi:10.1186/cc12685 · Cited by 977
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Ferraris, V. A., Saha, S. P., Oestreich, J. H., Song, H. K., Rosengart, T., Reece, T. B., Mazer, C. D., Bridges, C. R., Despotis, G. J., Jointer, K., et al. (2012) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2012.07.086 · Cited by 293
Self-citationDupanovic, M. (2015) · Encyclopedia of Trauma Care · doi:10.1007/978-3-642-29613-0_456
Metadata
- Authors
- Hall, R., & Mazer, C. D.
- Venue
- Anesthesia & Analgesia
- Published
- 2011-02
- Volume
- 112
- Issue
- 2
- Pages
- 292-318
- ISSN
- 0003-2999 (ISSN-L)
- OpenAlex
- W2049222615
- Cited by
- 203
- References
- 11
- FWCI
- 12.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period. https://app.cochat.ai/papers/10.1213/ane.0b013e318203f38d
- The paper
- Hall, R., & Mazer, C. D. (2011). Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0b013e318203f38d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.